Harrow (HROW) Cash & Current Investments (2010 - 2026)
Harrow's (HROW) quarterly Cash & Current Investments came in at $94.6 million in Q1 2026, up 41.84% year-on-year from $66.7 million in Q1 2025, and up 29.78% quarter-over-quarter from $72.9 million in Q4 2025.
Harrow (HROW) Cash & Current Investments (2010 - 2026) Analysis & Trends
Harrow's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $94.6 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 41.84% year-over-year to $94.6 million in Q1 2026; TTM through Mar 2026 was $94.6 million, a 41.84% increase from a year earlier, with the FY2025 full-year figure at $72.9 million, up 54.35% from the prior year.
- Cash & Current Investments grew to $94.6 million in Q1 2026 per HROW's latest filing, from $72.9 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $101.9 million in Q4 2022 and bottomed at $26.9 million in Q1 2023.
- The 5-year median for Cash & Current Investments is $71.0 million (2024), against an average of $64.4 million.
- Across the five-year window, Cash & Current Investments soared 677.83% in 2022 and slumped 46.87% in 2023, its largest moves.
- Year by year, Cash & Current Investments stood at $101.9 million in 2022, then decreased by 18.74% to $82.8 million in 2023, then tumbled by 42.91% to $47.2 million in 2024, then surged by 54.35% to $72.9 million in 2025, then gained by 29.78% to $94.6 million in 2026.
- Per Business Quant, the three latest HROW Cash & Current Investments figures stand at $94.6 million (Q1 2026), $72.9 million (Q4 2025), and $74.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Harrow | 1.39 Bn | 1.30 Bn | 27.05 Mn | 94.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.64 Mn |
| Dec 31, 2025 | 72.93 Mn |
| Sep 30, 2025 | 74.29 Mn |
| Jun 30, 2025 | 52.96 Mn |
| Mar 31, 2025 | 66.73 Mn |
| Dec 31, 2024 | 47.25 Mn |
| Sep 30, 2024 | 72.60 Mn |
| Jun 30, 2024 | 70.97 Mn |
| Mar 31, 2024 | 75.97 Mn |
| Dec 31, 2023 | 82.77 Mn |
| Sep 30, 2023 | 73.88 Mn |
| Jun 30, 2023 | 29.67 Mn |
| Mar 31, 2023 | 26.88 Mn |
| Dec 31, 2022 | 101.86 Mn |
| Sep 30, 2022 | 49.12 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | 50.59 Mn |
| Dec 31, 2021 | 50.67 Mn |
| Sep 30, 2021 | 67.85 Mn |
| Jun 30, 2021 | 85.06 Mn |